These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34840127)

  • 1. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
    Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
    Moutinho-Ribeiro P; Batista IA; Quintas ST; Adem B; Silva M; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Medas R; Lopes S; Vilas-Boas F; Baptista M; Dias-Silva D; Esteves AL; Martins F; Lopes J; Barroca H; Carneiro F; Macedo G; Melo SA
    World J Gastroenterol; 2022 Aug; 28(31):4310-4327. PubMed ID: 36159010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
    Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
    Frampton AE; Prado MM; López-Jiménez E; Fajardo-Puerta AB; Jawad ZAR; Lawton P; Giovannetti E; Habib NA; Castellano L; Stebbing J; Krell J; Jiao LR
    Oncotarget; 2018 Apr; 9(27):19006-19013. PubMed ID: 29721179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
    Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
    Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
    Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
    Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
    Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Guo S; Qin H; Liu K; Wang H; Bai S; Liu S; Shao Z; Zhang Y; Song B; Xu X; Shen J; Zeng P; Shi X; Chen H; Gao S; Xu J; Pan Y; Xiong L; Li F; Zhang D; Jiao X; Jin G
    Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.
    Martínez-Bosch N; Cristóbal H; Iglesias M; Gironella M; Barranco L; Visa L; Calafato D; Jiménez-Parrado S; Earl J; Carrato A; Manero-Rupérez N; Moreno M; Morales A; Guerra C; Navarro P; García de Frutos P
    EBioMedicine; 2022 Jan; 75():103797. PubMed ID: 34973624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
    Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
    Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
    Melo SA; Luecke LB; Kahlert C; Fernandez AF; Gammon ST; Kaye J; LeBleu VS; Mittendorf EA; Weitz J; Rahbari N; Reissfelder C; Pilarsky C; Fraga MF; Piwnica-Worms D; Kalluri R
    Nature; 2015 Jul; 523(7559):177-82. PubMed ID: 26106858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.